CompuNet Now Offers BRCA Genetic Testing to Assess Hereditary Breast and Ovarian Cancers Risks
December 10, 2013 – Dayton, OH – CompuNet Clinical Laboratories has announced the availability of BRCA1 and BRCA2 mutation testing through its relationship with Quest Diagnostics. The suite of four tests, called BRCAvantage™, identifies mutations in the BRCA1 and BRCA2 genes which are associated with increased risk of breast and ovarian cancers in women and increased risk for prostate and breast cancers in men.
The American Cancer Society states that about 5% to 10% of breast cancer cases are thought to be hereditary, resulting directly from gene mutations inherited from a parent. The most common cause of hereditary breast cancer is an inherited mutation in the BRCA1 and BRCA2 genes. The risks associated with BRCA1 and BRCA2 mutations include a 50-85% risk for developing breast cancer and a 10-45% risk for developing ovarian cancer, according to the Ohio Department of Health.
Film actress Angelina Jolie brought national attention to BRCA this past summer when she tested positive for the BRCA mutation. Because of her increased cancer risk, Ms. Jolie made the decision to undergo a double mastectomy.
A BRCA mutation genetics evaluation is recommended in the following situations:
- There is a personal or family history of known BRCA mutation
- Individual has had ovarian cancer
- Individual has had breast cancer with one or more of the following:
- diagnosed at ≤50 years of age
- is Ashkenazi Jewish
- has bilateral breast cancer
- has triple negative breast cancer
- has male breast cancer
- has personal or family history of ovarian, pancreatic, prostate, sarcoma, adrenocortical, brain, endometrial, thyroid, leukemia, lymphoma, or diffuse gastric cancer
- Two people on the same side of the family have had breast cancer
Genetic counselors play an important role in helping an individual decide whether or not they should have BRCA mutation testing and they can help an individual who tests positive for the BRCA mutation weigh their options. As part of the BRCAvantage™ offering, both physicians and patients have access to third-party genetic counselors.
For more information about the BRCA mutation or testing, contact your healthcare provider. Here are some resources for more BRCA information:
Susan G. Komen Foundation: http://ww5.komen.org/
Quest Diagnostics: http://www.brcavantage.com/
National Cancer Institute: http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA
For more information contact: Kim Stanforth, Director - Marketing & Communications